The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of PepGen Inc.(PEPG) Shareholders

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and its clinical study, CONNECT2 [1][2]. Group 1: Allegations Against PepGen Inc. - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen's lead product candidate, PGN-EDO51, was less effective and safe than previously claimed [1]. - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval purposes [1]. - The lawsuit claims that PepGen was likely to halt the CONNECT2 study, and the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated [1]. Group 2: Class Action Details - Shareholders who purchased shares of PEPG during the specified class period are encouraged to register for the class action, with a deadline of August 8, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Group 3: The Gross Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].